Authored By: Sarah
15 Jul 2024

 Celiac Diseases Drugs Market Size to grow by USD 1101.1 million between 2024-2028

According to a research report “ Celiac Diseases Drugs Market” by Therapy (First line treatment, Second-line treatment) Route Of Administration (Oral, Parenteral) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1101.1 million, at a CAGR of almost 21.21% during the forecast period. Celiac disease is a condition marked by elevated gluten deposits in the body, primarily due to the frequent intake of foods rich in this protein. Gluten is commonly found in various consumer staples such as pizza, cakes, soups, beer, bread, cookies, pasta, and burgers. The global consumption of fast food, particularly pizza and burgers, has been on the rise. In the US, pizza consumption remains moderate, yet significant. Similarly, beer production and consumption have experienced substantial growth over the last decade. Moreover, the increasing per capita income in both developed and developing economies has led to a surge in beer consumption, potentially increasing the risk for celiac disease patients.

Browse market data tables, figures, and in-depth TOC on “Celiac Diseases Drugs Market” by Therapy (First line treatment, Second-line treatment) Route Of Administration (Oral, Parenteral) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Therapy, the First line treatment segment is projected to dominate the market size in 2024


By Route Of Administration, Oral  segment is expected to hold the largest market size for the year 2024

The celiac disease market's initial treatment phase primarily revolves around prevention and cure methods, with the gluten-free diet serving as the current frontline solution. This diet is effective in mitigating immune responses and preventing the manifestation of various clinical symptoms. However, the absence of approved drugs for celiac disease management presents a significant opportunity for growth. Notably, several drugs are under fast-track approval processes and are anticipated to enter the market during the forecast period, potentially generating substantial revenue due to the current unmet medical need.

North America is forecasted to hold the largest market size by region in 2024

The Celiac Diseases Drugs Market represents a significant business opportunity due to the rising prevalence of celiac disease and growing awareness of gluten-intolerance. Key players in this market include Alvogen, Dr. Reddy's Laboratories, and Intas Pharmaceuticals, who are developing and marketing gluten-free drugs to cater to this niche patient population. Market growth is driven by increasing diagnoses, regulatory approvals, and advancements in drug technology.

The Celiac Diseases Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • 9 Meters Biopharma Inc
  • Adaptive Biotechnologies Corp.
  • Almirall SA
  • Amgen Inc.
  • AMYRA Biotech AG
  • Artielle Immunotherapeutics Inc
  • Avaxia Biologics Inc.
  • BioLineRx Ltd.
  • Bristol Myers Squibb Co.
  • Calypso Biotech BV
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • ImmunogenX Inc.
  • Johnson and Johnson Services Inc.
  • Precigen Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vactech Oy
  • Zedira GmbH

For insights on company offerings- Request a sample report!

Research Analysis Overview

Coeliac disease is an autoimmune disorder triggered by the bodily reaction to gluten, a protein found in rye, barley, and wheat. Precision medicine and healthcare systems are focusing on pharmaceutical interventions for this genetic disorder, which affects approximately 1% of the population. Pharma companies are developing drug formulation technologies to create gluten-free versions of existing medications, ensuring they do not contain traces of gluten. However, for many individuals with Coeliac disease, a strict gluten-free diet remains the primary treatment. Complications from non-adherence to the diet can include abdominal distention, diarrhea, gastrointestinal malfunction, infertility, neurological disorders, and low bone density. The high healthcare expenditure associated with managing these complications highlights the need for effective pharmaceutical interventions. As the demand for gluten-free options grows, ready-to-use packaged food and pharmaceuticals are becoming increasingly important. Pharmaceutical interventions offer a solution for those who struggle with strict dietary adherence, but they come with potential side effects and high costs. The integration of precision medicine and drug formulation technology in the treatment of Coeliac disease is a promising development, but more research is needed to determine their long-term safety and efficacy.

Market Research Overview

Celiac Disease, an autoimmune disorder, affects healthcare professionals and patients worldwide. This condition arises due to an adverse reaction to gluten, a protein found in rye, barley, and wheat. The unmet medical need for effective pharmaceutical treatments is significant, as many patients face complications such as malnutrition, weight loss, lack of appetite, ion imbalance, dehydration, stomach swelling, bloating, anorexia, and distension. The patient pool for Celiac Disease includes both women and men, with diagnostic options ranging from blood tests to small bowel biopsies. Immunomodulatory therapies and precision medicine are emerging areas of interest in Celiac Disease research. Drug delivery technology and pharmaceutical interventions are being explored to mitigate the bodily reaction to gluten. Pharmaceutical companies are investing in celiac drug innovation, with clinical trials underway. However, the complications of Celiac Disease extend beyond the gastrointestinal system, affecting infertility cases, diabetes type 1, neurological disorders, and low bone density. The diagnostic process can be misdiagnosed, leading to prolonged dietary deprivation and antigen-exposure. Governments and private organizations are collaborating to increase healthcare expenditure for Celiac Disease research and treatment. Universities are also contributing to the advancement of diagnostic options and drug formulation technology. As the understanding of immune profiles and genetic markers evolves, the future of Celiac Disease treatment looks promising.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!